Switch theme
Sign up to access all valuation multiples
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
2017
n/a
LTM Revenue $42.9M
Last FY EBITDA -$24.9M
$59.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NRX Pharmaceuticals has a last 12-month revenue (LTM) of $42.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, NRX Pharmaceuticals achieved revenue of n/a and an EBITDA of -$24.9M.
NRX Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NRX Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $42.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $37.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$24.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$4.3M | XXX | -$18.5M | XXX | XXX | XXX |
| EBIT Margin | -10% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$8.9M | XXX | -$25.1M | XXX | XXX | XXX |
| Net Margin | -21% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, NRX Pharmaceuticals's stock price is $3.
NRX Pharmaceuticals has current market cap of $56.4M, and EV of $59.2M.
See NRX Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $59.2M | $56.4M | XXX | XXX | XXX | XXX | $-0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, NRX Pharmaceuticals has market cap of $56.4M and EV of $59.2M.
NRX Pharmaceuticals's trades at n/a EV/Revenue multiple, and -2.4x EV/EBITDA.
Equity research analysts estimate NRX Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NRX Pharmaceuticals has a P/E ratio of -6.4x.
See valuation multiples for NRX Pharmaceuticals and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $56.4M | XXX | $56.4M | XXX | XXX | XXX |
| EV (current) | $59.2M | XXX | $59.2M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.4x | XXX | XXX | XXX |
| EV/EBIT | -13.8x | XXX | -3.2x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.4x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNRX Pharmaceuticals's last 12 month revenue growth is 122%
NRX Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
NRX Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NRX Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NRX Pharmaceuticals and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 122% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NRX Pharmaceuticals acquired XXX companies to date.
Last acquisition by NRX Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . NRX Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was NRX Pharmaceuticals founded? | NRX Pharmaceuticals was founded in 2017. |
| Where is NRX Pharmaceuticals headquartered? | NRX Pharmaceuticals is headquartered in United States of America. |
| Who is the CEO of NRX Pharmaceuticals? | NRX Pharmaceuticals's CEO is Dr. Jonathan C. Javitt,M.D.,M.P.H.. |
| Is NRX Pharmaceuticals publicy listed? | Yes, NRX Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of NRX Pharmaceuticals? | NRX Pharmaceuticals trades under NRXP ticker. |
| When did NRX Pharmaceuticals go public? | NRX Pharmaceuticals went public in 2021. |
| Who are competitors of NRX Pharmaceuticals? | Similar companies to NRX Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of NRX Pharmaceuticals? | NRX Pharmaceuticals's current market cap is $56.4M |
| What is the current revenue of NRX Pharmaceuticals? | NRX Pharmaceuticals's last 12 months revenue is $42.9M. |
| What is the current revenue growth of NRX Pharmaceuticals? | NRX Pharmaceuticals revenue growth (NTM/LTM) is 122%. |
| What is the current EV/Revenue multiple of NRX Pharmaceuticals? | Current revenue multiple of NRX Pharmaceuticals is 1.4x. |
| Is NRX Pharmaceuticals profitable? | Yes, NRX Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
